The STELLAR trial is now recruiting patients with recurrent anaplastic astrocytoma.
Patients with anaplastic astrocytoma that has recurred or progressed after surgery or biopsy, radiation therapy, and chemotherapy may be eligible to participate in the STELLAR trial.
There are currently no targeted therapies for patients with this rare disease. That’s why brain cancer experts at Orbus Therapeutics are conducting the STELLAR trial to evaluate the use of eflornithine oral solution — a targeted therapy — for treating recurrent anaplastic astrocytoma.
The STELLAR trial, a phase 3 clinical trial, is now recruiting participants at selected medical centers participating trial sites page in the United States, Belgium, Germany, and Italy.
"The few available treatments for anaplastic astrocytoma have limited efficacy"
For patients with radiographically (MRI) suspected anaplastic astrocytoma, surgery is the initial recommended approach for reducing tumor size and pathologic diagnosis.
After surgery, adjuvant radiation therapy is generally considered to be the standard of care for the treatment of patients diagnosed with AA.
After surgery and radiation therapy, patients typically receive some form of chemotherapy (e.g. temozolomide or Temodar®). Currently, there are limited options for physicians treating AA with chemotherapy. The available chemotherapies provide some benefit to patients, but effect is modest, and toxicities limit long-term use in AA patients.
Since there is a need for better treatment options for patients diagnosed with AA, we are evaluating eflornithine in a clinical study. Patients with AA who have progressed or recurred following surgery, RT and chemo may be eligible for participation in our clinical trial.